Resolute Science, a San Diego, CA-based preclinical-stage biotechnology company, received an investment from NuFund Venture Group.
The company intends to use the funds to advance its lead asset, RS-5, a MAC-TAC carrying an MMAE payload, through IND-enabling studies and submission.
Led by CEO and Founder Dr. Faith H. Barnett, Resolute Science is advancing a pipeline of synthetic drug conjugates to deliver targeted cytotoxic and radiotherapeutics deep into tumors. The modular design of its MAC-TAC (macrophage targeted conjugate) platform enables the rapid development of drug candidates carrying a variety of payloads. Its approach has the potential to overcome the resistance mechanisms associated with cancer-cell targeting therapeutics, delivering more effective and well-tolerated treatments to patients who have run out of options.
RS-5 has demonstrated potent single-agent anti-cancer efficacy in 16 preclinical studies across multiple tumor models while being well tolerated.
As part of the investment, NuFund’s John Montana will join Resolute Science as a board observer. Additionally, James Mackay, a NuFund member and existing Senior Business Advisor to Resolute, will join Resolute’s Board of Directors.
FinSMEs
12/02/2025